DK2940013T3 - HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND - Google Patents

HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND Download PDF

Info

Publication number
DK2940013T3
DK2940013T3 DK13868493.1T DK13868493T DK2940013T3 DK 2940013 T3 DK2940013 T3 DK 2940013T3 DK 13868493 T DK13868493 T DK 13868493T DK 2940013 T3 DK2940013 T3 DK 2940013T3
Authority
DK
Denmark
Prior art keywords
biphenyl
amino
carbonyl
ethoxy
thiophen
Prior art date
Application number
DK13868493.1T
Other languages
Danish (da)
English (en)
Inventor
Noriaki Iwase
Hiroshi Nishida
Makoto Okudo
Masaaki Ito
Shigeyuki Kono
Masaaki Matoyama
Shigeru Ushiyama
Eiji Okanari
Hirofumi Matsunaga
Kenji Nishikawa
Tomio Kimura
Original Assignee
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries filed Critical Ube Industries
Application granted granted Critical
Publication of DK2940013T3 publication Critical patent/DK2940013T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/36Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
DK13868493.1T 2012-12-28 2013-12-27 HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND DK2940013T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012286425 2012-12-28
JP2013097171 2013-05-02
PCT/JP2013/085277 WO2014104372A1 (ja) 2012-12-28 2013-12-27 ハロゲン置換へテロ環化合物

Publications (1)

Publication Number Publication Date
DK2940013T3 true DK2940013T3 (en) 2018-03-26

Family

ID=51021433

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13868493.1T DK2940013T3 (en) 2012-12-28 2013-12-27 HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND
DK18157384.1T DK3360869T3 (da) 2012-12-28 2013-12-27 Halogen-substitueret heterocyklisk forbindelse anvendelig til behandlingen af sygdomme forårsaget af lpa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18157384.1T DK3360869T3 (da) 2012-12-28 2013-12-27 Halogen-substitueret heterocyklisk forbindelse anvendelig til behandlingen af sygdomme forårsaget af lpa.

Country Status (13)

Country Link
US (2) US10000463B2 (enExample)
EP (2) EP3360869B1 (enExample)
JP (3) JP6176258B2 (enExample)
KR (1) KR102189166B1 (enExample)
CN (2) CN104884447B (enExample)
AU (1) AU2013366898B2 (enExample)
BR (1) BR112015015275B1 (enExample)
CA (1) CA2896701C (enExample)
DK (2) DK2940013T3 (enExample)
ES (2) ES2825031T3 (enExample)
MX (1) MX369801B (enExample)
RU (2) RU2649398C2 (enExample)
WO (1) WO2014104372A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2649398C2 (ru) * 2012-12-28 2018-04-03 Убе Индастриз, Лтд. Галогензамещенное гетероциклическое соединение
EA033923B1 (ru) 2013-03-15 2019-12-10 Эпиджен Байосайенсиз, Инк. Гетероциклические соединения, применимые в лечении заболеваний
JP2014231508A (ja) * 2013-05-02 2014-12-11 宇部興産株式会社 ハロゲン置換へテロ環化合物
KR102433588B1 (ko) * 2014-06-27 2022-08-19 우베 가부시키가이샤 할로겐 치환 헤테로환 화합물의 염
KR20180082564A (ko) * 2015-11-20 2018-07-18 우베 고산 가부시키가이샤 Nash의 치료 또는 예방을 위한 의약 조성물
KR20220039718A (ko) * 2019-07-30 2022-03-29 다이쇼 세이야꾸 가부시끼가이샤 Lpa1 수용체를 길항하는 우레아 화합물
JP7431961B2 (ja) 2019-11-15 2024-02-15 ギリアード サイエンシーズ, インコーポレイテッド Lpa受容体アンタゴニストとしてのトリアゾールカルバメートピリジルスルホンアミド及びその使用
AU2021282986B2 (en) 2020-06-03 2024-03-07 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CN111909170B (zh) * 2020-09-11 2022-08-12 吉林奥来德光电材料股份有限公司 一种有机电致发光化合物、其制备方法以及包含该有机电致发光化合物的有机电致发光器件
TWI818538B (zh) 2021-05-11 2023-10-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
WO2022241023A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
EP4444707A1 (en) 2021-12-08 2024-10-16 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
US12180414B2 (en) 2022-12-12 2024-12-31 Bmic Llc Downstream uses for briquettes and other forms of powder from asphalt shingle waste

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420878T1 (de) 2000-02-18 2009-01-15 Kyowa Hakko Kirin Co Ltd Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
ATE447970T1 (de) 2001-02-08 2009-11-15 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
JP4692281B2 (ja) * 2003-08-05 2011-06-01 味の素株式会社 新規アゾール化合物
BRPI0920825A2 (pt) 2008-09-29 2015-12-22 Lilly Co Eli modulador seletivo do receptor de estrogênio
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
IN2012DN00754A (enExample) 2009-08-04 2015-06-19 Amira Pharmaceuticals Inc
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011091167A2 (en) 2010-01-22 2011-07-28 The General Hospital Corporation Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases
US20130253019A1 (en) 2010-06-15 2013-09-26 John Howard Hutchinson Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
WO2011159633A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
WO2011159635A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions
CA2820817A1 (en) 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof
EP2648726B1 (en) 2010-12-07 2018-04-04 Amira Pharmaceuticals, Inc. Polycyclic lpa1 antagonist and uses thereof
CN103596947A (zh) * 2011-04-05 2014-02-19 艾米拉医药股份有限公司 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2013025733A1 (en) 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
RU2649398C2 (ru) * 2012-12-28 2018-04-03 Убе Индастриз, Лтд. Галогензамещенное гетероциклическое соединение

Also Published As

Publication number Publication date
ES2667798T3 (es) 2018-05-14
RU2756506C2 (ru) 2021-10-01
BR112015015275A8 (pt) 2019-10-22
KR20150100756A (ko) 2015-09-02
RU2649398C2 (ru) 2018-04-03
CA2896701A1 (en) 2014-07-03
EP2940013A4 (en) 2016-08-03
CN107698555A (zh) 2018-02-16
US10597375B2 (en) 2020-03-24
RU2018109925A (ru) 2019-02-27
EP2940013A1 (en) 2015-11-04
WO2014104372A1 (ja) 2014-07-03
JP6414286B2 (ja) 2018-10-31
JP6176258B2 (ja) 2017-08-09
AU2013366898A1 (en) 2015-08-13
EP2940013B1 (en) 2018-02-21
CN104884447A (zh) 2015-09-02
EP3360869A1 (en) 2018-08-15
US20150376160A1 (en) 2015-12-31
JP6569792B2 (ja) 2019-09-04
DK3360869T3 (da) 2020-10-12
RU2018109925A3 (enExample) 2020-12-03
AU2013366898B2 (en) 2017-06-29
BR112015015275A2 (pt) 2017-07-11
EP3360869B1 (en) 2020-07-29
US20180258062A1 (en) 2018-09-13
JP2019014739A (ja) 2019-01-31
RU2015131139A (ru) 2017-02-03
CN104884447B (zh) 2017-10-10
ES2825031T3 (es) 2021-05-14
BR112015015275B1 (pt) 2021-12-14
JP2017214410A (ja) 2017-12-07
CA2896701C (en) 2020-10-06
CN107698555B (zh) 2020-05-05
JPWO2014104372A1 (ja) 2017-01-19
MX369801B (es) 2019-11-21
MX2015008479A (es) 2015-09-23
US10000463B2 (en) 2018-06-19
KR102189166B1 (ko) 2020-12-09

Similar Documents

Publication Publication Date Title
DK2940013T3 (en) HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND
CN102015606B (zh) IRE-1α抑制剂
AU2014275643B2 (en) Heterocyclic derivatives and use thereof
AU2015281021B2 (en) Salt of halogen-substituted heterocyclic compound
JP2009500329A (ja) アミノ−5−(6員)ヘテロアリールイミダゾロン化合物およびβ−セレクターゼ調節のためのその使用
CA2506799A1 (en) Mixed lineage kinase modulators
AU2017290233A1 (en) 1 H-pyrazol-1 -YL-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof
US7820700B2 (en) 2-phenylpyridine derivative
KR20250002355A (ko) At2r 작용제
TWI359810B (en) Carboxylic acid derivative containing thiazole rin
TW200946117A (en) Compounds having NPY Y5 receptor antagonistic activity
TW201602089A (zh) 多環性herg活化劑
JP2018039733A (ja) 新規複素環誘導体
CA3220193A1 (en) Novel oxazole derivative and pharmaceutical composition for preventing or treating allergic diseases comprising the same
US20070010564A1 (en) Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7511065B2 (en) Mixed lineage kinase modulators
JP2006036730A (ja) 新規ピロール誘導体
TW201546050A (zh) 新穎苯并氮呯衍生物及其醫藥用途